drugset
drugset / Trial / NCT02061449

Poly ICLC, Radiation, and Romidepsin for Advanced Cutaneous T Cell Lymphoma

NCT02061449 ↗

Phase 1 Terminated 3 enrolled NYU Langone Health Ludwig Institute for Cancer Research · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study evaluates the safety and tolerability of the addition of immunostimulatory therapy consisting of focal radiation with or without the Toll-like receptor (TLR) agonist Poly ICLC in patients with cutaneous T-cell lymphoma (CTCL) receiving concurrent therapy with the histone deacetylase inhibitor (HDACI) Romidepsin.

Timeline

Start
2014-03
Primary completion
2018-11-05
Completion
2018-11-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Hiltonol Other / unclassified — Subcutaneous
Background Romidepsin Peptide — Intravenous

Indications

primary cutaneous T-cell lymphoma